Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.
|Articles|May 30, 2017
US Generics Market Set for More "Dynamic Growth"
Advertisement
The global generics market has experienced dynamic growth in recent years, registering a compound annual growth rate (CAGR) of 11.1% between 2012 and 2016 to reach a value of $318 billion, according to data from research company MarketLine. The company’s
The US once reigned supreme as the single biggest country market, with a value of $99.7 billion. MarketLine predicts the US market will grow with a CAGR of 7.2% between 2016 and 2021, to reach a value of $141.2 billion. Europe is expected to see slower growth, with the company projecting a CAGR of 5.6% for the 2016-2021 period, driving the market to a value of $65.1 billion in 2021.
Advertisement
Related to this article
AbbVie partners with Iambic on AI-driven drug discovery as Telix Pharmaceuticals moves to acquire ITM Isotope Technologies in a multibillion-dollar radiopharmaceutical merger, Novo Nordisk's CagriSema outperforms Eli Lilly's tirzepatide in a head-to-head diabetes trial, and Jen Lamppa of Inovalon discusses how real-time clinical data is reshaping trial recruitment.
AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Advertisement
Advertisement
Trending on PharmExec
1
CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report
2
Roundup: AbbVie & Iambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM
3
Understanding the Latest with MFN Pricing and What It Means to Pharma
4
The Battle to Own the GLP-1 Patient Journey
5